What is the recommended evaluation and management for a patient with restrictive lung disease?

Evaluation and Management of Restrictive Lung Disease

For patients with restrictive lung disease, establish the underlying etiology through spirometry showing FVC <80% predicted with FEV1/FVC >0.7, followed by high-resolution CT chest, and measure DLCO and total lung capacity to guide specific management strategies.

Initial Diagnostic Evaluation

Pulmonary Function Testing

• Spirometry is essential to confirm restrictive pattern: FVC ≤80% predicted with FEV1/FVC ratio >0.7 1
• Measure DLCO and total lung capacity (by body plethysmography or washout technique) to assess severity and differentiate intrinsic vs extrinsic causes 2
• FEV1 correlates better with symptom severity than TLC in restrictive disease and may be more useful for monitoring 3
• Assess respiratory muscle strength with maximal inspiratory and expiratory pressures, particularly when neuromuscular disease or chest wall deformity is suspected 1

Critical caveat: In patients with skeletal abnormalities (kyphoscoliosis, short stature), use arm span instead of height for predicted values, as standard equations may overestimate lung function 1

Oxygenation Assessment

• Measure pulse oximetry at rest and with exertion at baseline and every 3-6 months 4
• Perform 6-minute walk test with continuous oximetry monitoring 2
• Prescribe supplemental oxygen if saturation drops below 88% during exercise or if resting PaO2 <7.3 kPa (55 mmHg) 2, 5
• Consider transcutaneous PCO2 monitoring overnight in neuromuscular disease to detect nocturnal hypoventilation before daytime hypercapnia develops 6

Imaging and Further Testing

• High-resolution CT chest is mandatory to identify the specific pattern and extent of disease 2, 7
  • For idiopathic pulmonary fibrosis: Look for definite UIP pattern with honeycombing, subpleural reticulation, and traction bronchiectasis 2
  • Quantify extent: fibrotic changes involving ≥5% of lung volume define progression from interstitial lung abnormality to interstitial lung disease 7
• Chest radiograph to assess thoracic cage anatomy and chronic changes 1
• Consider bronchoalveolar lavage if infection or hypersensitivity pneumonitis suspected (>30% lymphocytes argues against IPF) 2

Etiology-Specific Management

Idiopathic Pulmonary Fibrosis

Antifibrotic therapy with pirfenidone or nintedanib should be initiated to slow disease progression 2, 8

• Pirfenidone monitoring: LFTs at baseline, monthly for 6 months, then every 3 months 2
• Discontinue smoking (increases pirfenidone metabolism); avoid concomitant omeprazole 2
• Vaccinations: Annual influenza and pneumococcal vaccination 2
• Lung transplantation referral for patients <65 years with DLCO <39% predicted or FVC decline >10% over 6 months 2

Neuromuscular Disease and Chest Wall Deformity

Initiate home non-invasive ventilation (NIV) when nocturnal hypoventilation is documented or chronic hypercapnic respiratory failure develops 9, 6

• Start NIV if: daytime hypercapnia present, nocturnal hypoventilation on transcutaneous PCO2 monitoring, or orthopnea with sleep disturbances 6
• NIV is superior to invasive mechanical ventilation in this population 9
• Monitor peak cough flow: values <160 L/min indicate inadequate cough; consider mini-tracheostomy combined with NIV rather than intubation 9
• Specialized physiotherapy for secretion clearance is mandatory 9

Acute Exacerbations

For acute worsening (<30 days) with new ground-glass opacities on imaging after excluding infection, pulmonary embolism, and heart failure 2:

• High-dose corticosteroids are standard treatment 2
• Consider intravenous cyclophosphamide 2
• Rule out pulmonary embolism, pneumothorax, infection, and aspiration 4

Supportive Management (All Causes)

Oxygen Therapy

• Long-term oxygen therapy (LTOT) prolongs survival in severe hypoxemia (PaO2 <7.3 kPa at rest) 2, 5
• Prescribe for ≥15 hours daily 5

Pulmonary Rehabilitation

• Initiate respiratory rehabilitation programs for patients with exercise limitation causing significant impairment 2, 10
• Home-based programs are effective and include: breathing retraining, exercise training, respiratory muscle exercises, level walking 10
• Benefits include improved walking distance, respiratory muscle strength, quality of life, and reduced dyspnea 2, 10
• May not be feasible in advanced disease 2

Monitoring and Follow-up

• Every 3-6 months: spirometry (FVC, FEV1), DLCO, pulse oximetry at rest and with exertion 4
• Screen for complications: pulmonary hypertension (requires right heart catheterization for confirmation, not echocardiography), lung cancer, coronary disease 4
• In neuromuscular disease on NIV: review ventilator data for adherence, leaks, and upper airway obstruction patterns; perform polygraphy and transcutaneous PCO2 monitoring to optimize settings 6

Nutritional Support

• Monitor body mass index and fat-free mass (stronger predictor of survival than BMI alone) 11
• Address malnutrition aggressively (prevalence 9-55% in ILD) 11

Key pitfall: Do not rely on echocardiography to diagnose or assess severity of pulmonary hypertension in fibrotic lung disease—it is inaccurate and requires right heart catheterization for confirmation 4.